Skip to main content
OpenTrials
Completed

NCT Number: NCT06682585

Nutritional Status and Therapy in DMD Patients

Brief Summary

The goal of this clinical trial is to evaluate the impact of a disease-specific, individualized diet on the nutritional status and functional abilities of Duchenne muscular dystrophy (DMD) patients. The study will focus on children aged 4-8 years residing in Ankara, Turkey.

Key questions the investigators aim to answer:

Can a tailored dietary intervention improve the nutritional status of DMD patients? Does a specialized diet positively impact the functional abilities of DMD patients, as measured by the North Star Ambulation Assessment (NSAA)? Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements, and will receive individualized dietary counseling. The intervention will focus on optimizing energy, protein, calcium, and fluid intake, as well as addressing the potential side effects of corticosteroid therapy.

The primary outcome measure will be changes in nutritional status, as assessed by anthropometric measurements. Secondary outcome measures will include changes in functional abilities as measured by the NSAA and quality of life assessments.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Study Objective This study aims to investigate the efficacy of a disease-specific, individualized dietary intervention in improving the nutritional status and functional abilities of Duchenne Muscular Dystrophy (DMD) patients aged 4-8 years residing in Ankara, Turkey.

Study Design This is a prospective, interventional study. Intervention

A 12-week individualized dietary intervention will be implemented for each participant. The intervention will focus on:

  • Energy Intake: Caloric needs will be calculated based on the patient's age, weight, and activity level, taking into account the potential impact of corticosteroid therapy on energy expenditure.
  • Protein Intake: Protein requirements will be met through a balanced diet, aiming to optimize muscle protein synthesis.
  • Calcium and Vitamin D Intake: Adequate intake of these nutrients will be emphasized to support bone health and prevent osteoporosis.
  • Fluid Intake: Fluid intake will be monitored to prevent dehydration and constipation.
  • Carbohydrate Intake: A low-glycemic index diet will be recommended to manage blood glucose levels and insulin resistance, especially in patients on corticosteroid therapy.
  • Sodium Intake: Sodium intake will be restricted to minimize fluid retention and hypertension.

Outcome Measures Changes in anthropometric measurements (body weight, height, BMI, skinfold measurements) Changes in functional abilities as assessed by the North Star Ambulation Assessment (NSAA) Changes in functional abilities as assessed by handgrip strenght Changes in micro and micro nutrient intake as assessed by three-day food consumption record Data Collection Data will be collected through face-to-face interviews with parents or primary caregivers and patients with DMD. After the first interview, a second interview will be conducted 12 weeks after the personalized diet has been planned.

Baseline Assessment:

  • Demographic information
  • Medical history
  • Nutritional assessment (anthropometric measurements, dietary intake assessment)
  • Functional assessment (NSAA)

Follow-up Assessments:

  • Anthropometric measurements
  • Functional assessment (NSAA)
  • Dietary intake assessment Data Analysis Statistical analysis will be performed using appropriate statistical software. Descriptive statistics will be used to summarize the baseline characteristics of the participants. Parametric or non-parametric tests will be used to compare pre- and post-intervention outcomes, as appropriate.

Ethical Considerations The study will be conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee. Informed consent will be obtained from the parents or legal guardians of the participants.

By addressing the specific nutritional needs of DMD patients, this study aims to improve their overall health and quality of life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Duchenne Muscular Dystrophy (DMD) Must be between 4 and 8 years old Able to ambulate independently Must be residing in Ankara province, Turkey Must be willing to participate and adhere to the dietary intervention, as confirmed by both the patient and their legal guardian(s) Must be currently receiving corticosteroid therapy

Exclusion criteria

Inability to read and write in Turkish Wheelchair-bound or unable to ambulate independently Significant liver or kidney dysfunction Scheduled for major surgery within 6 months of study enrollment Symptoms of dysphagia and swallowing difficulties Significant respiratory distress or respiratory insufficiency requiring mechanical ventilation.

Treatment and study plan

Individualised dietary intervention

Other
  • Energy Intake: Caloric needs will be calculated based on the patient's age, weight, and activity level, taking into account the potential impact of corticosteroid therapy on energy expenditure.
  • Protein Intake: Protein requirements will be met through a balanced diet, aiming to optimize muscle protein synthesis.
  • Calcium and Vitamin D Intake: Adequate intake of these nutrients will be emphasized to support bone health and prevent osteoporosis.
  • Fluid Intake: Fluid intake will be monitored to prevent dehydration and constipation.
  • Carbohydrate Intake: A low-glycemic index diet will be recommended to manage blood glucose levels and insulin resistance, especially in patients on corticosteroid therapy.
  • Sodium Intake: Sodium intake will be restricted to minimize fluid retention and hypertension.

Primary outcomes

  1. Anthropometric measurements

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in body weight (kg). Body weight will be measured with an electronic scale sensitive to 0.1 kilograms.

  2. Anthropometric measurements

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in skinfold thickness (triceps, biceps, subscapular, and suprailiac) (in millimeters) Skinfold thickness will be compared to the World Health Organization's percentile and Z score charts to determine adequacy, deficiency, or excess.

  3. Anthropometric measurements

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in height (cm). Height is measured with the individual standing upright and the head in the Frankfurt plane (the orbitale point and tragion point are set to be on the horizontal plane), while the vertical distance from the ground to the vertex, which is the highest point of the head, will be measured with a tape measure on a fixed plane.

  4. Anthropometric measurements

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in Body Mass Index (BMI)(kg/m²). BMI will be obtained by dividing the particioant's body weight in kg by the square of the height in meters.

    Body mass index will be evaluated with the World Health Organization's percentile and Z score charts.

Secondary outcomes

  1. Functional Ability

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in the North Star Ambulation Assessment (NSAA) score meausered by a specialist physiotherapist. The total score varies between 0-34. A higher score indicates better ambulation and motor function.

  2. Functional Ability

    Time frame: From enrollment to the end of diet at 12 weeks

    Changes in hand grip strength measured by hand dynamometry (in kilograms)

Other outcomes

  1. Dietary Adherence

    Time frame: From enrollment to the end of diet at 12 weeks

    After the dietary intervention, 3-day food consumption records will be taken again. The 3-day food consumption records before and after the dietary intervention will be examined. The compatibility of the latest consumption records with the macro and micronutrients of the recommended diet and the differences between the first 3-day food consumption record will be examined. The computer program called BeBIS will be used for the analysis of macro and micronutrients.

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Registry information

Official study title

Determination of Nutritional Status of Duchenne Muscular Dystrophy Patients and Evaluation of the Effectiveness of Disease-Specific Nutrition Therapy

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 12, 2024
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.